Promising results for AMD treatment with targeted radiotherapy
Stereotactic radiotherapy (SRT) seems to offer a safe and efficacious treatment for neovascular age-related macular degeneration (AMD), with patients achieving a statistically significant reduction in ranibizumab retreatment after 24 months, according to Timothy L Jackson PhD, FRCOphth.
Dr Jackson presented the results of the INTREPID study, the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy (IRay™, Oraya Therapy) in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD.
A total of 21 sites in five European countries participated in the trial with a total enrolment of 230 patients. Of this group, 226 received the allocated treatments of 16 Gray (N=74), 24 Gray (N=73) or sham SRT (N=79).
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.